About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 414 record(s)
Req # A-2019-001318
Adverse Reaction Reports (AERs) for Mezavant and Mesalazine. Report numbers: E2B_02173512, E2B_02176202, E2B_02196619, 000718959, E2B_02173280.Organization: Health Canada
October 2020
Req # A-2020-000956
Copy of any document concerning the corporation and building located at: 2800 TransCanada Highway, City of Pointe-Claire, Quebec, owner: Hypertec Infrastructures Inc.Organization: Health Canada
October 2020
Req # A-2020-000961
The most current Risk Management Plan (RMP) and RMP review report for Novolin (Insulin) associated with any of the following Drug Identification Numbers (DIN): 02024217, 02025248, 02024314, 02024322, 02024225, 02024233, 02024268, 02024284 by Novo Nordisk Canada Inc.Organization: Health Canada
October 2020
Req # A-2019-000782
Adverse Reaction Reports (AERs). Report numbers: E2B_00448180, E2B_01009098, E2B_00230367, 000671194, E2B_00515963, E2B_00386685, 000554445, E2B_00008389, E2B_00055045.Organization: Health Canada
October 2020
Req # A-2019-001135
Adverse Reaction Reports (AERs) for Cipralex® (escitalopram), Celexa® (citalopram). Report numbers: E2B_02360546, E2B_02360553, E2B_02347860, 000723059, E2B_02388486, E2B_02400247, E2B_02408243, 000723278, 000723402, 000725546.Organization: Health Canada
October 2020
Req # A-2019-001184
Adverse Reaction Reports (AERs) for GLYCERYL TRINITRATE. Report numbers: 000720235, 000726685, E2B_01766543, 000721626, 000727110, 000727321, E2B_02074491, 000724086, 2018196419, E2B_01904234, E2B_01995949, E2B_02502672, 000726947, 2018503440, E2B_02275905.Organization: Health Canada
October 2020
Req # A-2019-001226
Adverse Reaction Report (AER). Report number: E2B_02472669.Organization: Health Canada
October 2020
Req # A-2019-001246
Adverse Reaction Report (AER). Report number: E2B_02471483.Organization: Health Canada
October 2020
Req # A-2019-001473
Adverse Reaction Reports (AERs). Report numbers: E2B_02297675, E2B_02295498.Organization: Health Canada
October 2020
Req # A-2019-001651
Adverse Reaction Reports (AERs) for PETHIDINE HYDROCHLORIDE. Report numbers: 000723100, E2B_02151255, 000723343, E2B_02204757, E2B_02236089, E2B_02245056, 725078, E2B_02345551, E2B_02043056, E2B_02161523.Organization: Health Canada
October 2020